Providing independent clinical excellence since 2005
Posted on Tuesday March 5, 2024 in Naked Heart
The Naked Heart began as a cardiology education project.
After 35 years in the NHS and 25 years as an interventional consultant cardiologist, I had treated thousands of patients with established cardiovascular disease — blocked arteries, unstable plaques, myocardial infarction and heart failure.
The Naked Heart was created to explain cardiovascular disease clearly — to patients, professionals and anyone who wanted to understand how the heart works and why it fails.
It focused on:
It was about stripping cardiology back to fundamentals.
But over time, a deeper question emerged.
Much of my career was defined by what might be called Cardiology 2.0.
This was the era of:
It transformed survival. It was lifesaving and technically extraordinary.
But it was reactive.
By the time we were inserting a stent, disease was already advanced.
We had become exceptionally good at opening arteries.
We had not fully addressed why they were narrowing.
As imaging advanced, the field began to shift.
Coronary CT allowed earlier detection of plaque. Calcium scoring identified subclinical disease. Preventive therapies became more aggressive and more targeted.
Yet even this left a fundamental issue unresolved.
Atherosclerosis is not simply an anatomical narrowing.
It is a biological and inflammatory process driven by metabolic stress.
And that recognition marks the arrival of Cardiology 3.0.
It focuses not just on plaque, but on the processes that create plaque.
This era is defined by:
This is no longer simply about seeing blockages.
It is about identifying biological stress before structural damage becomes critical.
Three years after launching The Naked Heart, one pattern became increasingly clear.
Most cardiovascular disease shares upstream drivers:
At the centre of this network lies visceral adipose tissue (VAT).
Visceral fat is not passive. It is metabolically active. It drives inflammatory signalling, disrupts insulin regulation and accelerates vascular injury.
You may not see it.
Body mass index may not reflect it.
But CT can measure it.
The VAT Trap describes the modern condition in which individuals appear outwardly well yet carry hidden metabolic risk that silently accelerates cardiovascular disease.
In Cardiology 3.0, VAT is not a cosmetic issue.
It is a measurable biological driver.
The Naked Heart explains the heart.
The VAT Trap explains why the heart becomes diseased.
Together they represent a progression:
From anatomy
To inflammation
To metabolism
Both The Naked Heart and The VAT Trap are hosted at:
The platform integrates cardiology, imaging, artificial intelligence and metabolic science with one goal:
Earlier understanding.
Earlier intervention.
Fewer catastrophic events.
We have mastered the art of opening arteries.
The next era is about preventing them from narrowing in the first place.
Cardiology 3.0 is not the abandonment of intervention. It is the refinement of prevention.
The heart was the starting point.
Metabolism is the frontier.
And the VAT Trap sits at the centre of that shift.
I agree to receive your Naked Heart blog article notifications and accept the data privacy statement.
We use Brevo as our marketing platform. By submitting this form you agree that the personal data you provided will be transferred to Brevo for processing in accordance with Brevo’s Privacy Policy.
In cardiometabolic medicine, muscle is not a cosmetic tissue but a metabolic organ. Evidence consistently shows that strength, not muscle mass, predicts insulin resistance, cardiovascular risk, and survival. Many older adults are not losing muscle tissue — they are losing muscle function, and that is the pathology that matters.
Annual health screenings represent a valuable investment in employee well-being, offering significant benefits for both employees and employers. If you are a company or HR director you may be interested in the UK tax breaks around annual health check, which may give you and your employees access to our cutting edge health screening programs without its costs being viewed by HMRC as benefit in kind.
A 2026 BMJ systematic review confirms that weight regain is the rule after stopping pharmacological weight-management therapy. Across drug classes, most lost weight is regained within 24 months, with parallel loss of metabolic benefit. This reflects biological defence of adiposity, not patient failure.
Diastolic heart failure (often referred to as 'Heart failure with preserved Ejection Fraction' or 'HFpEF') arises from ventricular stiffening due to age, hypertension, and various other rarer heart conditions. The aging component of this process is unavoidable, but maintaining optimal blood pressure through midlife is achievable and, if successful, should prevent additional left ventricular stiffening attributed to hypertension. By regularly monitoring blood pressure and using effective medication, we can help patients live longer with healthier hearts.